

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **BIOSENTA INC.** (the "Issuer").

Trading Symbol: **ZRO**

Number of Outstanding Listed Securities: **23,006,592**

Date: **December 01, 2022**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) *Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.*
- (b) *The term "Issuer" includes the Issuer and any of its subsidiaries.*
- (c) *Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.*

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact

As disclosed in a press release dated October 12, 2022, the Company has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. ("Voran") which will lead the way for the commercialization of Biosenta's Tri-Filler® antimicrobial products in Canadian markets and worldwide. The patented new material science Tri-Filler® products could set the new standard in antimicrobial materials as a safe and proactive option against biological and ecological threats.

As disclosed in a press release dated May 25, 2022, the Company is developing environmentally friendly biocidal particles that are successfully tested against infectious bacteria growing on common surfaces. The particles are developed in collaboration with Dr. Maen Husein's laboratory, University of Calgary, and tested in Dr. Ian Lewis's laboratory, University of Calgary. Preliminary results showed that inclusion of the particles into cement provides effective biocidal attributes.

Further research will be conducted this summer on multiple construction surfaces such drywall, paint, plastic, glass carpet etc. Research funds from Biosenta are matched by Mitacs Accelerate funding that builds partnerships between academia, industry, and the world.

As disclosed in a press release dated March 21, 2022, the Company announced that it has entered into an agreement (the "Agreement") to settle \$1,015,088.47 of debt through the issuance of 3,625,315 common shares of the Company at a deemed price of \$0.28 per share and 1,812,658 warrants each exercisable for one common share of the Company with an exercise price of \$0.56 per share (the "Transaction"). The Transaction allows the Company to settle certain outstanding debts, however the transaction will not otherwise effect the Company's day-to-day business and affairs. Pursuant to this agreement, the Company issued 992,857 warrants and 1,985,714 shares to Amarvir Singh Gill to settle \$556,000.00 of indebtedness; 310,871 warrants and 621,741 shares to 1698791 Ontario Ltd. to settle \$174,087.56 of indebtedness; 376,604 warrants and 753,207 shares to 1943391 Ontario Ltd. to settle \$210,898.00 of indebtedness and 132,326 warrants and 264,653 shares to various additional creditors, including one employee of the company, to settle \$74,102.91 of indebtedness. The shares and warrants issued to 1698791 Ontario Ltd., and 1943391 Ontario Ltd. and certain other creditors are subject to a four month hold period under applicable securities legislation and the shares and warrants issued to Amarvir Singh Gill and certain other creditors are subject to a four month hold period unless approval is obtained from the Canadian Stock Exchange. The Transaction is considered a related party transaction subject to Multilateral Instrument 61-101 ("MI 61-101"). The Company is exempt from the formal valuation requirement as per section 5.5(b) of MI 61- 101 as the Company is listed only on the CSE, and no exchanges specified in 5.5(b) of MI 61-101. The Company is exempt from the need to obtain minority shareholder approval as per section 5.7(b) of MI 61- 101 as, in addition to being listed only on the CSE, neither the fair market value of the shares and warrants, nor the fair market value of the consideration received therefor exceeds \$2,500,000, each of the independent directors of Biosenta approved the Transaction, and neither Biosenta, nor, to the knowledge of Biosenta after reasonable inquiry, any party to the Transaction, has knowledge of material information regarding the Company that had not been previously disclosed.

After the Transaction, Amarvir Singh Gill (director of Biosenta, as well as President and Chief Executive Officer) will own and control 5,012,737 shares (including shares issuable upon exercise of warrants and options) representing 20.63% (he previously held 2,034,166 shares (including options) or 10.33%) of the issued and outstanding common shares of the Company (on a partially diluted basis).

1698791 Ontario Ltd. will own and control 4,430,997 shares (including shares issuable upon exercise of warrants) representing 18.98% (previously held 3,498,385 shares or 18.02%) of the issued and outstanding common shares of the Company (on a partially diluted basis). Bill Connor is the sole owner and controller of 1698791 Ontario Ltd. and does not own or control any additional shares, directly or indirectly, in Biosenta, except for the shares owned and controlled by 1943391 Ontario Ltd.

1943391 Ontario Ltd. will own and control 1,129,811 shares (including shares issuable upon exercise of warrants) representing 4.82% (previously held no shares) of the issued

and outstanding common shares of the Company (on a partially diluted basis). 1943391 Ontario Ltd. is 50% owned by 1698791 Ontario Ltd. and 50% owned by DK Financial Canada Inc.

DK Financial Canada Inc. will own and control 2,187,425 shares (having no shares issuable upon exercise of warrants) representing 9.49% (it previously held 2,187,425 shares or 11.27%) of the issued and outstanding common shares of the Company (on a partially diluted basis). DK Financial Canada Inc. is not participating in the Transaction, and is only indirectly involved in the Transaction pursuant to its interest in 1943391 Ontario Ltd. DK Financial Canada Inc. does not own or control any additional shares, directly or indirectly, in Biosenta, except for the shares owned and controlled by 1943391 Ontario Ltd.

Paul Kalata will own and control, both directly and indirectly through DK Financial Canada Inc. (of which he is the sole owner and controller), 2,228,491 shares (having no shares issuable upon exercise of warrants) representing 9.67% (he previously held 2,228,491 shares or 11.48%) of the issued and outstanding common shares of the Company (on a partially diluted basis). Paul Kalata is not participating in the Transaction, and is only indirectly involved in the Transaction pursuant to his indirect interest in 1943391 Ontario Ltd. Paul Kalata does not own or control any additional shares, directly or indirectly, in Biosenta, except for the shares owned and controlled by 1943391 Ontario Ltd.

As disclosed in a press release dated January 28, 2021, the Company announced that it will enter into a series of prime plus 5% unsecured promissory notes (the "Notes") in consideration for cash investments in the aggregate amount of \$85,000 (together, the "Investment"). The Investment will provide capital for the Company to meet the financial requirements of its day-to-day operations and to continue its strategic business plan to grow the company and to capture the growing trend for safe, consumer, commercial and industrial disinfectant with anti-microbial compounds. The Notes will become fully due and payable six (6) months from their date of issue along with interest calculated on the basis of a 365 day year for the actual days elapsed. The Investment will include an investment by Amarvir Singh Gill, Chief Executive Office, President and Director of the Company, in the amount of \$25,000, as well as investment by various other arm's length parties. The Investment is considered a related party transaction subject to Multilateral Instrument 61-101 ("MI 61-101") as Amarvir Singh Gill is considered a related party. The Company is exempt from the formal valuation requirement as per section 5.5(b) of MI 61-101 as the Company is listed only on the CSE, and no exchanges specified in MI 61-101. The Company is exempt from the need to obtain minority shareholder approval as per section 5.7(b) of MI 61-10 as neither the fair market value of the Notes, nor the fair market value of the consideration received therefor exceeds \$2,500,00 and each of the independent directors of Biosenta approved the Investment.

As disclosed in a press release dated January 26, 2021, the Company realized its first purchase order and payment from the supply and purchase agreement with SANITIZATION 360. The Purchase Order is for an initial order of 145 drums (30,160 litres) of TRUE disinfectant and continued monthly orders. This marks a milestone for the Company of achieving record revenues as it continues to implement its strategic plan to position the company to be a leader in the growing disinfectant market in North America. The agreement with SANITIZATION 360 is a perfect fit for the Company's growth plans and aligns itself with a company that sells leading edge disinfectants products

As disclosed in a press release dated December 22, 2020, Biosenta's U.S. licensing partner Kleen Bee Labs, LLC has secured licensing rights in Ralphs and Food 4 Less retailers, which are divisions of Kroger Corp. Kroger Corp is one of the largest retailers in

the US with approx. 2,400 stores. Kleen Bee Labs long term goal is to distribute in over 10,000 stores across the United States. Kleen Bee Labs' previously announced deal will ensure Biosenta's patented formulation will continue to expand and be sold at scale across North America. The distributor will cover all costs associated with marketing, warehousing, transportation logistics, and retail space fees.

As disclosed in a press release dated December 17, 2020, Biosenta's stock closed at 0.75 CAD +0.37 (97.37%). This marked the third day of Alberta's Province wide Covid-19 lockdown. This is in step with Biosenta's strategic business plan grow the company and to capture the growing trend for safe, consumer, commercial and industrial disinfectant with anti-microbial compounds. This comes on the eve of Biosenta receiving the patent for Canada. This is the first step for Biosenta to become a major player in the disinfectant, personal hygiene and anti-microbial categories meeting the market demand for products that are both safe and powerful. Biosenta will continue to implement strategies to grow the company in the next quarter by capitalizing on government and private sector contracts.

As disclosed in a press release dated September 24, 2020, the Company announced the finalization of a four-year research partnership with the University of Calgary Research Group and AMPAK Inc. from Toronto, Ontario, is official. This partnership enables the University team to undertake a new generation of research in the world of nanoparticles for use as an anti-microbial filler in commercial construction materials and plastic consumer products and goods packaging. The University of Calgary team has demonstrated expertise in this field, previously improving the tensile strength of concrete by 80%. The University of Calgary team has also improved the performance of drilling fluids and ceramic membranes using nanoparticle technology.

AMPAK Inc. is proud to be the first Industry research partner to commit to the project. The scope of AMPAK's involvement includes plastic product development, research and development, and commercial consumer packaging. The partnership's goal is to synthesize nanoscale core-shell particles and standardize the production process of the Company's patented two-part, food-grade nanoparticles called Tri-filler. Tri-filler not only has attributes of being anti-microbial, but also strength enhancement and fire-retardant capabilities. This innovation has the potential to revolutionize the antiviral properties of everyday surfaces such as clothes, paint, drywall, concrete, common surfaces and consumer packaging materials.

The project principal is actively looking to engage with businesses or commercial entities seeking to improve their products' and materials' anti-microbial properties.

The impact on the community is measurable and two-fold. Firstly, there is an incredible opportunity for local organizations that currently use nanoparticles as fillers to get involved in development and testing activities as research partners. Secondly, the University team has dedicated a significant portion of their efforts to measuring nanoparticles' impact on human health and their concentration levels within the body over time due to consistent exposure, even at minimal parts-per-million. The University team is implementing theories to safely integrate the nanoparticles within compounds to improve end-user safety and increase the filler's usability in multiple consumer applications.

As disclosed in a press release dated September 14, 2020, the Company has announced a strategic licensing partnership with Kleen Bee Labs was finalized today. This license will give the rights for distribution of DualXtiv, a broad-spectrum anti-microbial disinfectant, to club level, mass grocery, and retail chains across North America.

As disclosed in a news release dated June 23, 2020, the Company has announced its first purchase order for its disinfectant product called "True" in Canada. Originally our product was filed with the trademark "Erase" but we received approval for a name change to "TRUE" to be consistent with the name of Biosenta's disinfectant previously launched in the US. We have successfully tested our chemical specifications and are ready to launch True in large quantities. True has been approved by Health Canada as clinically proven to kill many different types of Viruses, Bacteria and Fungi.

True has been added to the List of Disinfectants for Use Against SARS-CoV-2 (COVID-19) on the Health Canada website.

As disclosed in a news release dated April 01, 2020, the Company has announced its first purchase order for its disinfectant product called "True" in the United States. Backed by scientific research and EPA approvals, TRUE is a powerful and safe product that kills many different Viruses, Bacteria, and Fungi. TRUE is different and better in that it is stable, and it prevents the regrowth of microbes. This first purchase order will enable our product to be introduced to the US marketplace. TRUE is available in 25 fluid ounce bottles, one-gallon jugs, and 55-gallon drums.

As disclosed in a news release dated February 28, 2020, the Company announced that it has entered into an agreement (the "Agreement") to settle \$327,907.59 of debt through the issuance of 3,279,075 common shares of the Company at a deemed price of \$0.10 per share and 1,604,538 warrants each exercisable for one common share of the Company with an exercise price of \$0.20 per share (the "Transaction"). Pursuant to this agreement, the Company issued 1,099,875 shares and 549,938 warrants to DK Financial Canada Inc. to settle \$109,987.50 of debt, 1,109,000 shares and 554,500 warrants to 1698791 Ontario Ltd. to settle \$110,900.00 of debt, 770,200 shares and 385,100 warrants to Amarvir Singh Gill to settle \$77,020.09 of debt and 300,000 shares and 150,000 warrants to various additional creditors, including one employee of the Company, to settle \$30,000.00 of debt. The shares and warrants issued to DK Financial Canada Inc., 1698791 Ontario Ltd. and certain other creditors are subject to a four month hold period under applicable securities legislation and the shares and warrants issued to Amarvir Singh Gill and certain other creditors are subject to a four month hold period unless approval is obtained from the Canadian Stock Exchange. The Transaction is considered a related party transaction subject to Multilateral Instrument 61-101 ("MI 61-101") as 1698791 Ontario Ltd. and Amarvir Singh Gill are considered related parties. The Company is exempt from the formal valuation requirement as per section 5.5(b) of MI 61-101 as the Company is listed only on the CSE, and no exchanges specified in MI 61-101. The Company is exempt from the need to obtain minority shareholder approval as per section 5.7(b) of MI 61-10 as, in addition to being listed only on the CSE, neither the fair market value of the shares and warrants, nor the fair market value of the consideration received therefor exceeds \$2,500,000, each of the independent directors of the Company approved the Transaction, and no party to the Transaction nor the Company had, to the knowledge of the Company after reasonable inquiry, knowledge of material information regarding the Company that had not been previously disclosed. 1698791 Ontario Ltd. is a related party pursuant to the fact that prior to the Transaction, it beneficially controlled over 10% of the Company's voting securities. Amarvir Singh Gill is a director of Biosenta, as well as President and Chief Executive Officer. After the Transaction, 1698791 Ontario Ltd., the Company's largest shareholder will own and control 3,498,385 shares representing 19.51% of the issued and outstanding common shares of the Company (on a partially diluted basis). Amarvir Singh Gill will own and control 1,740,766 shares representing 9.80% of the issued and outstanding common shares of the Company (on a partially diluted basis). DK Financial Canada Inc., will own and control, together with its related parties and associated entities, 2,074,092 shares representing 11.57% of the issued and outstanding common shares of the Company (on a partially diluted basis).

As disclosed in a press release dated August 27, 2018, the Company announced, in conjunction with Microbial Research Products, the Joint Venture (JV) Agreement announced on February 28, 2018, it has signed its first Royalty Agreement for its Tri-Filler patented technology with Polski Bazalt / STM Technology (STM). This five year exclusive arrangement will give STM worldwide rights for its basalt composite products. STM is forecasting to start using the product towards end of the year. All other terms and conditions are confidential.

As disclosed in a news release dated February 28, 2018, the Company announced that it has signed a five year Joint Venture (JV) agreement with investors to develop, market, and potentially grow the sales of its patented dry product, Tri-Filler. The JV is based in Parry Sound, Ontario and is owned 51% by the investors and 49% by Biosenta. The investors will contribute funds to operate the JV and at this time contribution will be determined after a formal business plan has been completed.

Also the investors will continue funding on-going Biosenta's operating costs, provide expertise to launch Tri-Filler, and in return Biosenta will license global rights to the intellectual property that pertains to Tri-Filler with no additional funding required by Biosenta. The investors will receive 60% of operating profits until the amounts invested by the investors in the JV have been repaid. After the amounts already invested by the investors have been repaid, the operating profits will be split 51% to the investors and 49% to Biosenta. In addition the agreement with New South Biolabs will subsequently be terminated as Biosenta will issue 1,666,666 shares at \$0.57 per share in the Company which is about 11.9% of total outstanding shares. Outstanding debt of \$565,682 already incurred (year-end secured loan) by the investors will then be eliminated.

2. Provide a general overview and discussion of the activities of management.

Core Business Strategy

The Company is developing two business units within the anti-microbial industry. Products within these business units are targeted to address the demand created by the mounting health and environmental concerns with mould. Mould can affect the immune system, nervous system, liver, kidneys, blood and cause brain damage.

Under the Company's Industrial Division, the Company plans to manufacture and distribute an anti-microbial filler called "Tri-filler". Calcium Carbonate is one of the most common fillers used industrially. It is susceptible like other fillers that hold moisture to attract mould. Annual global revenue in the calcium carbonate filler industry is likely to be more than 100 billion dollars. Biosenta will produce anti-microbial filler that performs 'filling' and 'bulking' functions like calcium carbonate. Biosenta's filler product will not attract moisture and consequently mould infestation. Biosenta's filler with its anti-microbial high pH core in individual particles will enhance commercial product life and eradicate a broad spectrum of known bacteria, fungi, algae and other micro-organisms by suppression of their reproduction. The Company had commissioned its production plant to produce the filler product located in Parry Sound, Ontario. It is currently produced test product for potential customers. On-going strategic review of how to integrate Tri-filler in to market is being explored.

Under the Company's Consumer Division, the Company has developed a line of retail anti-microbial products that will effectively kill mould, bacteria and fungi on contact and prevent regrowth. The Company has obtained the necessary government approvals from Health Canada for selling its initial product line called Zeromold™ in Canada in September 2012. The first shipments of the product started in October 2012 on a limited

basis within Canada. The Company has developed a patented second generation of this product generation currently called "True" and now is being sold in the US and Canada. All EPA and Health Canada approvals have been received for True.

The Company has recently added three experienced personnel in its core strategic team in order to achieve its mission of promoting, branding and marketing its products. In addition, the Company has also recently hired a consulting firm, which will facilitate and help the Company to launch and market its products across the region.

The Company has started generating revenue starting from the month of September 2020, which is expected to increase period by period as the current management is under discussions for various government organizations and industry partners to secure and formalize the sales orders. True™ products are now being sold in Canada, US, and South America. The license agreement with Kleen Bee Labs has started its marketing campaign and closed some good retail chain stores and received purchase orders for products in November. As Biosenta realises revenues from True™, discussions are underway of commissioning a Tri-filler plant as industry is looking to test in its production facilities.

The company has received its milestone royalty payment in the month of December. Revenues from other sources are also being realised. Significant interest is coming from many different areas for the True™ product. Biosenta was also featured in the Canadian media for its revolutionary disinfectant.

The Company is showcasing and testing its TRUE product line with leading Health care providers, property management companies and educational institutions having presence across Canada and US. These companies have expressed their interest in TRUE products due to their high quality and efficacy in the fight against COVID -19 pandemic. Discussions and final negotiations have been initiated and are currently in progress.

Industrial Division: Tri-Filler

The Company will manufacture and distribute proprietary anti-microbial filler, and/or sub-license the technology relating thereto. Calcium Carbonate is one of the most common fillers used industrially. It is susceptible like other fillers that hold moisture to attracting mould. The Company will produce anti-microbial filler that performs "filling" and "bulking" that will not attract moisture and consequently mould infestation. The Company's filler product with its anti-microbial high pH core in individual particles enhances commercial product life and eradicates a broad spectrum of known bacteria, fungi, algae and other micro-organisms by suppression of their reproduction.

As disclosed in a press release dated July 31, 2017, the Company announced it is in discussions with Polski Bazalt / STM Technology ("STM"), a company that produces basalt composite pallets, to implement a licensing agreement for TriFiller and to sell to STM a 1 tonne per hour plant to manufacture Tri-Filler. The agreement is expected to be finalized in the next few months. The Company will give a license to STM to manufacture and use Tri-Filler in its Poland-based operation that will supply pallets to the European Union. The founder and Chairman of STM, Stanley Rokicki, said that Tri-Filler will provide antimicrobial protection for the pallets and make them more suitable for applications related to food and medicine. Mr. Rokicki added that Tri-Filler also enhances the structural strength and fire retardant properties of the pallets as compared to fillers currently employed. The two companies have been collaborating for approximately two years while the testing and development of Tri-Filler has been finalized.

Consumer Division - Anti-Microbial Retail Product Line

Biosenta's household disinfectants and cleaners possess similar levels of efficacy as traditional disinfectants with significantly lower concentrations of active ingredients resulting in lower toxicity. These disinfectants and cleaners will kill 100% of potentially deadly mold, fungi, bacteria and viruses on contact and prevent regrowth. The disinfectants are very safe due to the very low toxicity. The Company has developed its first retail product line of anti-mould product called Zeromold™ and has made its first shipments in Canada starting in October 2012. The product rollout was limited for the fiscal years 2013 to 2015 due to limited cash flow and production control issues. As a result of the rollout of the product in Canada has been slow.

The Company's rollout of the product started in the last quarter of fiscal 2014. To date, Biosenta estimates that approximately 900 stores have received the product. Biosenta has also listed ZeroMold in two other retailers in Canada in the February and March 2015 time frame. The rollout to the stores was again limited as a result of limited working capital to finance the rollout to the different retailers.

As disclosed in a press release dated June 22, 2015, the Company announced that its disinfectant, called "True" has been approved by the Environmental Protection Agency (EPA) in the U.S.A. Further, the EPA has allowed True to not carry a warning, caution or danger label because it is very safe for human use.

True is a new disinfectant and cleaner which effectively kills a multitude of potentially deadly microbes (bacteria, viruses and fungi/ mould) with a formulation that has been shown to be very safe for use. The innovation which gives True its unique properties is that it is both a very powerful disinfectant and it contains very low levels of active ingredients which make it much less toxic and more safe.

Laboratory testing of True on a broad range of potentially deadly microbes has been conducted by a world-renowned institution. These standardized tests have shown True will kill 100% of the following microbes within a 10 minute contact time:

<u>Bacteria</u>	<u>Virus</u>	<u>Fungi</u>
Acinetobacter Baumannii	Adenovirus	Black mould
(ABC)	Chlamydia	Trichophyton
E. Coli	Ebola	mentagrophytes
Listeria	Enterovirus D68	
MRSA	H1N1	
Pseudomonas aeruginosa	Hepatitis	
Salmonella	Herpes	
Staphylococcus aureus	HIV	
	Influenza	
	Polio	
	Respiratory Syncytial Virus	
	Rotavirus	
	Swine Flu	
	Tuberculosis	
	Vaccina (pox virus)	

Note that the Ebola and Enterovirus D68 claims are based on scientific rationale as provided by the U.S. Center for Disease Control. Please refer to Biosenta.com for details of the laboratory testing.

In March 2015 the Company announced a third-generation disinfectant, to be called Purity, has been developed to possess faster anti-microbial action than True and with a low pH. Biosenta's product strategy is to provide products that are both safe and powerful, and Purity will fulfill this strategy and represent an innovative disinfectant relative to currently available disinfectants. Purity will be tested over the next two months at an independent laboratory to refine the formulation. The goal is to use Purity in hand sanitizer and wipes as well as a disinfectant.

The Company has issued a wet product patent (disinfectant formulation comprising calcium hydroxide and sodium hypochlorite) in the United States of America. The patent is pending approval in Canada and the European Union.

The Company has issued a dry product patent (method and apparatus for the preparation of calcium carbonate coated calcium hydroxide particles) in Canada, the United States of America, China, Israel, Saudi Arabia, Mexico. The patent is pending approval from the European Union.

On April 2020, Biosneta announced its first sale on the US for its "True" product.

On June 2020, Biosneta announced its first sale in Canada for its "True" product.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

See Section 1 above regarding the "True" production line and see Section 2 in the Consumer Division regarding the "Purity" production line.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Zeromold

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition

was to a Related Person of the Issuer and provide details of the relationship.

N/A

8. Describe the acquisition of new customers or the loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common shares & Warrants	3,625,316 common shares and 1,812,658 warrants	Issued in Mar 2022	Conversion of loan to equity
Common shares	1,085,038 common shares	Common shares issued in August 2021 pursuant to the exercise of common share purchase warrants	\$109,988 was paid for the exercise and funds are intended to be used for working capital, \$107,020 was used to reduce debts
Common shares	554,500 common shares	Common shares issued in June 2021 pursuant to the exercise of common share purchase warrants	\$110,900 was paid for the exercise and funds are intended to be used for working capital
Stock Options	1,017,000 stock options	Issued in May 2021	N/A
Stock Options	350,000 stock options	Issued in Mar 2021	N/A
Common shares & Warrants	3,279,075 common shares and 1,604,538 warrants	Issued in Feb 2020	Conversion of loan to equity

We have already discussed in question 1.

15. Provide details of any loans to or by Related Persons.
N/A
16. Provide details of any changes in directors, officers or committee members.
N/A
17. Discuss any trends which are likely to impact the Issuer, including trends in the Issuer's market(s) or political/regulatory trends.
N/A

Certificate Of Compliance

The undersigned hereby certifies that:

1. *The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.*
2. *As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.*
3. *The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).*
4. *All of the information in this Form 7 Monthly Progress Report is true.*

Dated December 01, 2022

Am Gill

Name of Director or Senior Officer

Signature: "Am Gill"

CEO and President

Official Capacity

Issuer Details <i>Name of Issuer</i>	<i>For Month End</i>	<i>Date of Report</i> YY/MM/DD
Biosenta Inc.	November 2022	2022/12/01
<i>Issuer Address</i> 18 Wynford Drive, Suite 704		
<i>City/Province/Postal Code</i> Toronto, Ontario M3C 3S2	<i>Issuer Fax No.</i>	<i>Issuer Telephone No.</i> (416) 410-2019
<i>Contact Name</i> Am Gill	<i>Contact Position</i> CEO&President	<i>Contact Telephone No.</i> (416) 410-2019
<i>Contact Email Address</i> info@biosenta.com	<i>Web Site Address</i> www.biosenta.com	